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Title 
Maternal and neonatal pneumococcal vaccination - where are we now? 
Abstract 
Pneumococcus is a significant pathogen in neonates and in early infancy, particularly as 
a cause of invasive disease in sub-Saharan Africa where nasopharyngeal carriage rates 
are also exceptionally high.  The pneumococcal-conjugate vaccines have now been rolled 
out in many high income settings and an increasing number of low and middle income 
countries.  They have been highly effective at preventing vaccine serotype disease in 
infants.  However, a window of susceptibility remains prior to the first vaccination at 
around six weeks of age.  This paper summarizes the data available on both maternal 
and neonatal vaccination to prevent disease in newborns and early infancy and considers 
the key challenges and next steps for research in the field  
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Introduction 
The last decade has witnessed important reductions in under-five mortality [1].  Despite 
this, most countries have fallen short of the rate of reduction required to meet 
Millennium Development Goal 4, which called for a two-third reduction in under-five 
mortality by 2015 [1].  Seventy percent of under-five mortality occurs in those under the 
age of one and of these, 40% occurs in neonates.  Globally, nearly half of all deaths in 
children under-five years of age happen in sub-Saharan Africa with a further one third of 
deaths occurring in south Asia [1].  Consequently, as we move into the new post-2015 
sustainable development agenda, child survival strategies that aim to reduce mortality in 
early infancy in low and middle income countries, have some of the greatest potential for 
life saving impact [2, 3]. Within sustainable development goal three, related directly to 
health, the aim is to reduce neonatal mortality to an absolute value of 12 per 1000 live 
births or fewer, irrespective of the starting rate in 2015. This goal reinforces the need for 
logistically feasible and economically viable strategies targeting disease in this age group 
[4].      
Pneumococcal carriage and disease in early infancy  
Streptococcus pneumoniae (pneumococcus) is a leading cause of childhood disease 
worldwide.  Recent estimates suggest it is responsible for around 11% of all deaths in 
children less than five years of age and that over half of these deaths occur in Africa with 
up to a further quarter occurring in Southeast Asia [5].  
Infants, particularly in low-income setting, become rapidly colonized with bacteria in the 
nasopharynx.  Data from The Gambia indicate that over 80% of infants will be colonized 
with the bacteria over the first two months of life [6, 7].  Similarly, over 50% 
colonization has been reported at two months of age in South India; around 70% by the 
age of three months in a study undertaken in Bangladesh [8, 9]; and close to 100% in 
indigenous infants in Australia by three to four months of age [10]   
Colonization is an immediate precursor to disease [11], and in settings with high 
colonization rates in early life, disease is likely to follow.  Reflecting this, a recent 
systematic review indicated that the pneumococcus was responsible for 16.5% (95% CI: 
13.5-20.1) of cases of community acquired neonatal sepsis in sub-Saharan Africa and 
was second only to Staphylococcus aureus in this setting.  Furthermore, across all low 
and middle income countries the bacteria was responsible for 31.8% (95%CI: 18.1 - 
45.6) of community acquired neonatal sepsis in infants between two and three months 
of age making it the most common invasive pathogen in this age group by a significant 
margin [12].  A recent review of bacterial isolates from cerebrospinal fluid (CSF) taken 
from infants under two months of age with suspected meningitis in Malawi identified the 
pneumococcus in 21.7% of samples taken in the first week of life.  Pneumococcus was 
second only to Group B streptococcus over this period.  Beyond the first week of life, 
41.9% of CSF isolates were identified as pneumococcus [13].  A comparable study 
aiming to identify the aetiology of invasive infection in Gambian infants over the first 
three months of life reported that 47% of cases of culture-proven meningitis were 
caused by pneumococcus [14].  Finally, an association has also been demonstrated, in 
indigenous Australian infants,  between the nasopharyngeal pneumococcal carriage and 
the occurrence of chronic suppurative ear infections [10]; a condition which is also 
reported with variable prevalence in sub-Saharan Africa and South and East Asia [15]. 
Once established, as early as the first two or three months of life in this indigenous 
infant population, the infection is associated with prolonged morbidity, including 
educational disadvantage, throughout childhood [10, 16, 17].  Of note, there are 
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currently limited data on the overall burden of disease from countries such as China and 
India which have large populations under five years of age; much less on the burden of 
disease in early infancy in these countries.  Consequently, certain figures are necessarily 
estimations [5].  In addition, the sole reliance on culture in the studies reviewed above 
will tend to under-estimate the frequency of pneumococcal infection in settings in which 
oral antibiotic use is widespread without prescription. Importantly, the data reviewed 
above are taken from a period before the established use of the pneumococcal conjugate 
vaccines (PCV) in low and middle income settings.  These vaccines have had significant 
impact not only on pneumococcal disease caused by serotypes in the vaccine but also on 
pneumococcal carriage of vaccine serotypes which will now be considered. 
Indirect protection from pneumococcal-conjugate vaccines in early infancy 
Pneumococcal-conjugate vaccines are currently recommended by the WHO within the 
Expanded Programme on Immunization (EPI) schedule according to either a '3+0' 
schedule administered at around six, 10 and 14 weeks of age or a '2+1' schedule with 
two doses given starting at around the same age, followed by a booster dose at between 
nine and 15 months [18, 19].  In either case, infants are not directly protected against 
pneumococcal disease - as a result of active immunization - until approximately two 
weeks after the primary schedule has been completed.  During introduction of PCV into 
National Immunization Programmes the '3+0' schedule may be preferable in those 
settings in which disease incidence peaks in infancy and where vaccine coverage is 
relatively poor beyond the infant primary series.  The '2+1' schedule may be more suited 
to those settings with a later peak of disease, as observed in higher income countries, 
and may offer enhanced or more sustained protection against certain serotypes [20].  
Nonetheless, both schedules have been implemented to good effect and any differences 
between them are likely to be limited once programs are established [20].   
The indirect effects of PCV vaccine introduction on individuals too old to have been 
vaccinated within EPI, have been demonstrated for vaccine-type (VT) invasive 
pneumococcal disease (IPD), VT nasopharyngeal carriage as well as for clinical 
pneumonia [21].  These effects have now been documented in high income and 
subsequently also in middle and low income countries including in sub-Saharan Africa 
[21-27].   
Herd protection against IPD in newborns, prior to the age of first vaccination, has also 
been demonstrated in high income settings [24, 25].  A prospective, population-based 
study was conducted in the United States, examining the rates of invasive pneumococcal 
disease (IPD) in infants between 0 and 90 days of age, before and after the introduction 
of the seven-valent pneumococcal conjugate vaccine into the routine programme.  At the 
time of introduction, the vaccine was recommended as a three dose schedule, starting at 
two months, for those under the age of six months, with two doses being recommended 
for those between six and 24 months.  A booster dose of the vaccine at between 12 and 
15 months was also recommended for infants who were under 12 months at the time of 
the primary series [28].  In the subsequent study, the rates of IPD in infants under 90 
days of age fell from 11.8 per 100 000 live births in the pre-vaccination era to 7.2 per 
100 000 live births in the post-vaccination era.  When examining IPD caused by VT 
pneumococci alone, the equivalent figures were 7.3 per 100 000 in the pre-vaccination 
era compared to 2.4 per 100 000 in the post vaccination era.  Nonetheless, 40% of IPD 
in infants aged under 90 days of age continued to be caused by VT pneumococci 4 years 
after introduction of PCV7 in a '3 + 1' schedule which included a catch-up campaign 
[24].  In a comparable study undertaken in the UK, the overall incidence rate of IPD in 
infants under 90 days of age showed a non-significant decline following vaccine 
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introduction.  Seven-valent VT isolates accounted for 44% of IPD in this age group in the 
pre-vaccination era, falling to 10.3% three to four years following vaccine introduction 
which again included a catch-up campaign targeting all those under two-years of age 
[25].  
At present, there are no published data examining the effects of PCV introduction on IPD 
in early infancy from middle or low income settings.  However, a study undertaken 
within a trial of a nine-valent pneumococcal conjugate vaccine in The Gambia examined 
VT pneumococcal carriage in the younger siblings (average age three months) of vaccine 
and placebo recipients and found no differences in the carriage rates between the two 
groups (VT carriage prevalence 35.3% and 37.1% in the younger siblings of those in the 
vaccine and placebo groups respectively (Risk Ratio (95% CI): 0.95 (0.78 - 1.16)) [29].  
Similarly, a study nested within a phase 3, community-randomized, efficacy trial 
undertaken within the Navajo and White Mountain Apache Indian communities in North 
America did not find differences in the VT colonization of two month old infants from 
communities in which the seven-valent PCV had been introduced compared to control 
communities [30].   
Whether these early data will translate into an ongoing burden of disease in early infancy 
in low income settings, once programmatic delivery is well established, remains to be 
seen.  Nonetheless, the epidemiology of the pneumococcus is very different in many low 
and middle income countries, from observations in those high income countries where 
the vaccines were first introduced. For example, in the Gambia, pneumococcal carriage 
remains high into adulthood - providing a continued reservoir for potential transmission 
to young infants. It is uncertain yet whether an adult pool of carriage will be reduced 
sufficiently by infant immunization to halt potential transmission. In a cluster-
randomized trial undertaken across villages in a rural part of The Gambia, vaccinating all 
children between two and 30 months of age reduced the carriage of VT pneumococcal 
serotypes in infants of less than two months of age by only around 10% - to 38%.  In 
contrast, additionally vaccinating older children and adults reduced carriage to 17% - a 
reduction of around 30% - confirming older children and adults as an important source 
for transmission to infants [31].  Consistent with this finding, recent modeling data from 
The Gambia suggest carriage of serotypes included within the 13-valent vaccine will 
continue at a level of between 25 and 40% - even assuming 100% coverage over a 20 
year period.  The same model predicts rapid VT elimination in all age groups in the UK, 
even at 80% coverage, highlighting the fundamental difference in transmission dynamics 
between these settings [32].   
Finally, any indirect protection which may be generated in infants is unlikely to impact on 
all serotypes equally.  Highly invasive strains such as serotypes 1 and 5 are rarely 
carried and hence may be less susceptible to indirect effects while causing a 
disproportionate amount of disease in Africa [33].  In The Gambia, data collected since 
the 13-valent PCV (PCV13) was introduced, demonstrate that serotypes 1 and 5 alone 
have continued to cause a significant proportion of IPD in infants below 5 months of age 
[34].  Thus, even if modest indirect protection against carriage is generated, it seems 
unlikely to entirely address invasive disease in this age group. 
Therefore, in summary, despite the increasingly widespread roll out of PCV within the 
infant EPI schedule of low and middle income countries and the associated herd 
protection the vaccines induce, a burden of disease related to VT pneumococcus in early 
infancy may persist and vaccination of pregnant women (maternal) and neonates 
therefore warrants ongoing consideration. 
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Pneumococcal vaccine use to prevent disease in early infancy 
Maternal vaccination 
There has been a recent renaissance of interest in the use of maternal immunization as a 
way to protect neonates and in some cases expectant mothers from infectious diseases 
prominent in either group.  Pathogens targeted include not only tetanus but also 
pertussis, influenza, and an increasing range of other agents causing morbidity and 
mortality these populations [35].  However, the approach is not a new one.  Trials 
examining the administration of the 23-valent pneumococcal polysaccharide vaccine to 
expectant mothers have already been undertaken in high income as well as in low and 
middle income countries and in widely distributed geographic areas (Table 1).  None of 
the studies reported any safety concerns related to the vaccine administered during 
pregnancy and reported a low level of local or systemic reactogenicity overall.   
Polysaccharide vaccines do not generally prevent colonization of the nasopharynx - even 
in the vaccine recipient (i.e. in this case the mother) [36].  This represents one of their 
major disadvantages over the polysaccharide-conjugate vaccines (e.g. Prevenar13™ and 
Synflorix™).  In addition, the antibodies generated by polysaccharide vaccines tend to be 
less efficiently transferred across the placenta than those generated by protein vaccines, 
including conjugate vaccines [37, 38].  This may reflect the predominate induction of 
IgG2 - the isotype for which active transport is least efficient - by the T-cell independent 
polysaccharides.  In contrast, IgG1 is the predominant IgG isotype generated with T-cell 
help and is most efficiently transported across the placenta [39-42].  However, of note, 
the only trial which has directly examined the transfer of the pneumococcal serotype 
19F-specific in comparison to tetanus toxoid-specific IgG, IgG1 and IgG2 reported a 
consistently lower placental transfer for the polysaccharide-specific antibodies 
irrespective of whether total IgG or the IgG1 or IgG2 isotypes were examined [43].  In 
this study the cord/maternal antibody ratio was above one only when tetanus toxoid-
specific IgG1 was examined, indicating an apparent inefficiency of antibody transport 
across the placenta for polysaccharides-specific antibodies in general, at least in this 
context [12].  This finding is supported by the other studies which have examined the 
phenomenon and have consistently reported transfer ratios of less than one for 
pneumococcal polysaccharide-specific IgG (Table 1).  In contrast, studies examining the 
transfer of protein-specific IgG report transfer ratios ranging from 1.3 to 1.6 for 
pertussis, (according to pertussis antigen examined), 1.6 for diphtheria toxoid and 
between 1.4 and 1.7 for tetanus toxoid [37, 38]. 
Despite the relative inefficiency of antibody transfer across the placenta, those studies 
which have examined the polysaccharide-specific IgG levels in the infant at delivery or 
prior to infant vaccination have generally reported higher antibody levels in the infants of 
mothers vaccinated during pregnancy compared to controls [43-47].  The half life of 
polysaccharide-specific antibody in the infant is subsequently variable and appears 
study- (or context) as well as pneumococcal serotype dependent.  The latter may reflect 
differences in the predominant isotypes generated against individual polysaccharides, 
although there is little data examining this in the context of pneumococcal vaccination.  
Some studies demonstrate antibody persistence above control at 5 months while in other 
studies the infants of vaccinated and control mothers are essentially indistinguishable 
based on serological measures within three to four months [43, 46-48].  The only study 
to estimate the time for the polysaccharide-specific antibody concentration to fall below 
the 0.35µg/mL correlate of protection was conducted in an HIV positive maternal 
population.  This study reported geometric mean concentrations (GMC) above the 
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threshold for a period of 0.6 months from birth for serotype 3 as compared to 2.0 and 
2.7 months for serotype 5 and serotype 6B respectively [49]. 
Four trials have also reported the effects of maternal pneumococcal polysaccharide 
vaccination on breast milk IgA.  In each case, the level of polysaccharide-specific IgA 
was higher in the breast milk in vaccinated compared to control mothers. Levels 
returned towards baseline by around six months in each case although with some 
variation in the exact time of sampling [16, 43, 47, 50].  Given the primary site of 
pneumococcal colonization in the nasopharynx, antibodies delivered in this way may 
reasonably be expected to provide local protection although there are no data to 
examine this directly. 
Three trials have reported pneumococcal nasopharyngeal colonization rates in infants 
born to mothers vaccinated with a 23-valent pneumococcal polysaccharide vaccine 
during pregnancy compared to controls.  In a study conducted in the United States, 
nasal washes were undertaken on infants between two and 15 months of age although 
an average of only 1.6 washes per child were obtained over this period and the time 
points are unclear.  At 2 months of age, no infants born to mothers who had been 
vaccinated and only eight percent of infant (3/36) who were born to mothers in the 
control group were colonized with pneumococcus (difference non-significant).  At 16 
months the equivalent figures were 16.6 percent (3/18) and 50 percent (19/38) 
(p=0.021).  No significant differences were detected in serotype distribution, a reflection 
of the low number of isolates overall.  The apparent difference in colonization at 16 
months is difficult to reconcile with the rates on antibody decay reported.  The GMC to 
the four serotypes tested had returned to baseline before seven months [47].  Two 
additional studies have reported overall pneumococcal colonization rates in infants at 
three and six months.  A study undertaken in Bangladesh reported that 50 percent of the 
infants were colonized with pneumococcus by three months and three-quarters by six 
months but these figures were unaffected by maternal polysaccharide vaccination [43].  
A Brazilian study reported that around 17 percent of infants were colonized at 3 months 
and by six months between 26 and 27 percent had carried the bacteria although again 
maternal vaccination did not alter the total pneumococcal carriage rates and serotype 
specific carriage was not reported [51] 
Pneumococcal disease outcomes (including meningitis, pneumonia, otitis media and 
mortality from acute lower respiratory infections) were reported in three trials but no 
significant differences were detected reflecting the small sample sizes and hence low 
event rates in each case [46, 47, 52]. 
The effect of maternal vaccination or maternally-derived antibodies on the subsequent 
response of the infant to their routine pneumococcal-conjugate vaccines is a further 
important consideration.  A single maternal vaccination trial, using the 23-valent 
pneumococcal polysaccharide vaccine, has examined this directly [48].  However, in this 
trial the subsequent born infants received a dose of the polysaccharide rather than the 
polysaccharide-conjugate vaccine at either seven or seventeen weeks.  Use of a 
polysaccharide vaccine in this way would no longer be recommended due to the poor 
immunogenicity and hyporesponsiveness associated with these vaccines in this age 
group; thus the findings must be interpreted with extreme caution [53].  For four of the 
six serotypes examined, neither the infants of the control (unvaccinated) nor of the 
vaccinated mothers made a two-fold rise in GMC following vaccination.  For the two 
remaining serotypes high pre-vaccination GMC continued fall despite vaccination at 
seven weeks although a small number of infants did have a two-fold rise in antibody 
concentrations.  Infants vaccinated at seventeen weeks, who had pre-vaccination 
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antibody concentrations close to that of the infants of unvaccinated mothers, made more 
reliable responses overall and ultimately ended up with higher GMC than either the 
control or early vaccination groups.  Consequently, some inhibitory effect of maternal 
antibodies is suggested [48].  A trial examining the use of a neonatal dose of the 
polysaccharide-conjugate vaccines, which will subsequently be described, also examined 
the relationship between the polysaccharide-specific GMC in cord blood and at 18 weeks 
in infants - following three doses of the same vaccine.  This trial reported a significant 
inverse relationship between the GMC at these two time-points, suggesting an inhibitory 
effect of maternal antibodies on the infant responses to the primary series [54].                              
A Cochrane systematic review, updated most recently early in 2015, reviewed the data 
available regarding the potential role of pneumococcal vaccination during pregnancy in 
preventing infant infection.  Reflecting the sizes of the trials and their inconsistent 
findings, the review concluded that 'There is insufficient evidence to assess whether 
pneumococcal vaccination in pregnancy could reduce infant infections' [55].   
A single, randomized trial conducted in the United States between November 2000 and 
March 2003, although only published at the end of 2014 and hence absent from the 
systematic review cited above, examined the effects of maternal vaccination with an 
unlicensed nine-valent pneumococcal conjugate vaccine at 30 to 35 weeks gestation 
(n=74), and is the only study thus far to describe maternal vaccination with a PCV.  
Expectant mothers in the control group of the same trial (n=78) received a placebo 
injection of normal saline at the same time-point.  The trial examined pneumococcal 
antibody transfer across the placenta and also the responses of the infants to routine 
vaccination with the seven-valent PCV at two, four, six and 12 months.  Data on the 
occurrence of otitis media in infants over the first 12 months of life were also extracted 
retrospectively from the records of the primary care provider. No information regarding 
the cause of the otitis media or on rates of pneumococcal carriage was collected.  The 
vaccine was reported to be well tolerated by maternal and infant participants.  Cord 
blood antibody concentration in the infants born to mothers who had been vaccinated 
with the nine-valent vaccine were between 3.0 and 22.8 fold higher according to 
serotypes than in infants born to mothers in the unvaccinated control group.  The mean 
antibody concentration increased in both groups following the vaccine administered to 
infants at six and 12 months with a vigorous anamnestic response occurring in both 
groups following the pneumococcal conjugate vaccine 12 month booster.  Nonetheless, 
the final mean concentrations were lower for all the serotypes included in the seven-
valent vaccine at seven months and for four of the seven serotypes at 13 months in the 
maternal vaccination group.  The paper did not report seroprotection rates although the 
mean concentrations for all serotypes were at least three-fold above the 0.35ug/mL 
widely used correlate at seven months and at least 10-fold above the same cut off at 13 
months irrespective of group.   
Based on clinical findings documented during visits to family physicians, the study 
reported higher rates of otitis media over the first six months of life in the infants of 
those mothers who had received the conjugate vaccine during pregnancy than in the 
placebo group (32% in the vaccine group and 16% in the placebo group, p = 0.03).  No 
difference in the proportion of infants diagnosed with otitis media between six and 12 
months was noted (58% in the vaccine group and 56% in the placebo group, p = 0.87).  
The age at which the first episode of acute otitis media occurred was also significantly 
lower in the maternal vaccination group (15 days) compared to the control group (114 
days).  Of note, a sibling history of grommet insertion and a history of upper respiratory 
tract infections were more strongly associated with otitis media than the group into 
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which a mother had been randomized (p<0.01 and p<0.001 respectively).  Furthermore, 
although the trial was reported to be double-blind, mothers were asked at six months 
which vaccine they thought they had received and their response also had a borderline 
association with otitis media rates (p=0.09) making blinded nature of the results 
somewhat difficult to interpret and they should therefore be interpreted with caution. No 
other disease endpoints were described [56]. 
Finally, the PneuMum trial group has recently reported the results of a randomized 
controlled trial examining the impact of maternal 23-valent pneumococcal polysaccharide 
vaccination on middle ear disease amongst indigenous infants in the Northern Territory 
of Australia [16].  The trial enrolled a total of 227 eligible women who were randomized, 
in equal number into one of three groups.  The first received a dose of the 23-valent 
vaccine at 30 to 36 weeks gestation; the second a dose of the same vaccine within 72 
hours of delivery; the third (control) group was not vaccinated as part of the trial.  The 
trial's co-primary endpoints were the point prevalence of middle ear disease and the 
point prevalence of 23-valent vaccine-type pneumococcal carriage in the infants at seven 
months.  The trial was not blinded although an independent assessor confirmed or 
refuted the diagnosis of middle ear disease made by an un-blinded research nurse.  The 
independent assessor was blinded to both group and to the diagnosis of the research 
nurse thus reducing although not removing any bias associated with the assessment.  
Although the trial met the recruitment targets set, power was reported to be 
compromised due to the lower than expected rates of middle ear disease and 
nasopharyngeal carriage in the control infants. 
The trial demonstrated no impact of maternal vaccination on either of the primary 
endpoints.  Vaccine efficacy against ear disease at seven months was 13% (95% CI -
12% to 31%) and against carriage was 30% (95% CI -35% to 64%) at the same time 
point.  A post hoc analysis was undertaken to look at concurrent ear disease and 
carriage of the pneumococcal serotypes present in the 23-valent vaccine plus vaccine-
related serotype 6A (as a surrogate for ear disease caused by these vaccine types).  The 
vaccine efficacy against this exploratory, derived endpoint was 51% (-2% to 76%) in the 
maternal vaccination group.  In contrast, there was no evidence of comparable efficacy 
when looking at the association between ear disease and carriage of other pneumococcal 
serotypes or other bacteria (non-typeable Haemophilus influenzae or Moraxella 
catarrhalis) suggesting a genuine, albeit only borderline significant result [16].                
Neonatal vaccination 
Two trials have been published assessing the effects of a neonatal dose of the 7 valent 
pneumococcal conjugate vaccine [54, 57].  In the first trial, undertaken in Kenya, 300 
neonates were randomized in equal number, to receive the seven valent vaccine at 
either birth, 10 and 14 weeks or according to the routine EPI schedule at six, 10 and 14 
weeks.  The study reported no significant difference in the solicited or un-solicited safety 
events between the two groups.  At 18 weeks, four weeks following the completion of 
the infant schedule in both groups, there was no difference between groups in terms of 
the proportion of infants who had an antibody concentration above a protective threshold 
of >0.35µg/mL.  However, when a more conservative threshold of > 1.0µg/mL was used 
the respective percentages for three (4, 18C, 19F) of the seven serotypes were lower in 
the neonatal vaccination group.  For four (4, 9V, 18C, 19F) of the seven vaccine 
serotypes the GMC were also lower in the neonatal vaccination group compared to the 
routine group at the same point.  In contrast, the mean avidity indices were significantly 
higher for three of the four serotypes tested (4, 6B, 19F) in the neonatal compared to 
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the control group reflecting, presumably, the longer duration over which affinity 
maturation had occurred following the dose of the vaccine at birth [54].   
At 36 weeks, 20 weeks following the primary schedule, there was no difference in the 
percentage of infants with an antibody concentration above either the 0.35µg/mL or 
1.0µg/mL comparing the two groups although the serotype 4 GMC remained lower and 
the serotype 19F avidity index remained higher in the neonatal compared to the control 
group [54].   
The study reported no evidence of immunological tolerance resulting from the 
administration of the seven-valent vaccine at birth, as judged by the comparable 
response to a booster pneumococcal conjugate vaccine given at 36 weeks [54].   
Carriage was measured only at 18 and 36 weeks in this study.  No significant differences 
in carriage were detected between groups at either point although, in keeping with the 
difference in the GMC between the two groups, the VT carriage tended to be higher and 
the non-vaccine type (NVT) carriage lower in the neonatal group at both time points 
[54]. 
In the second trial, undertaken in Papua New Guinea, 318 infants were randomized into 
one of three groups to receive PCV7 according to a birth, one and two month (neonatal) 
schedule or a one, two and three month (infant) schedule.  The third group did not 
receive the vaccine (control).  A low level of local reactogenicity was reported overall 
although the levels were higher in the infant group compared to neonatal group.  There 
were no differences in the illness episodes or serious adverse events captured across the 
groups.  At two months of age, the GMC were significantly higher in the neonatal group 
than in the infant group (following two doses and one dose of PCV7 respectively) for four 
(4, 9V, 18C, 19F) of the seven VT in PCV7.  By four months, following three doses of the 
vaccine in both groups the situation had reversed and the GMC were significantly higher 
for all serotypes in the infant group than in the neonatal group (one and two months 
after the third doses of the vaccine respectively).  Both the neonatal and the infant 
groups responded to a subsequent challenge with a pneumococcal polysaccharide 
vaccine at nine months, generating comparable anamnestic responses.  The fold-rise in 
GMC was significantly greater in the vaccinated groups than in the control group for all 
serotypes following the neonatal schedule and for five of the seven serotypes following 
the infant schedule suggesting at least comparable memory induction between the two 
regimens and further supporting the absence of tolerance following vaccination in 
newborns [57].     
Expert commentary 
The pneumococcal vaccine field has continued to evolve since the pneumococcal 
conjugate vaccines were licensed and first introduced into routine infant immunization 
schedules.  Initial introduction in high income countries has now been followed by 
routine use in many low and middle income countries, thanks to WHO endorsement and 
GAVI purchasing with 126 countries using PCV to date.  Geographical differences in 
pneumococcal epidemiology, dominant carriage and disease-causing serotypes and 
prevalence of nasopharyngeal carriage in different age groups has meant that the impact 
of PCV in diverse settings has not been uniform.  
Contributing factors to diverse outcomes have included the presence of a catch up 
campaign targeting children too old to have been vaccinated according to the routine 
schedule, largely implemented only in high income countries.  Different vaccination 
schedules, including two or three infant priming doses with or without a booster dose 
have also been used and variable levels of vaccine coverage within the target age groups 
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have been achieved.  All of these factors have complicated the analysis of optimal 
strategies for PCV introduction and maintenance of control of VT disease. Consequently, 
a significant volume of work both in the form of clinical trials and post-introduction 
disease surveillance continues.       
Indirect protection has played an important role in the demonstrated effectiveness of the 
pneumococcal conjugate vaccines so far and has impacted on disease, not only in older 
children and adults, but also in infants too young to have been vaccinated. Such effects 
have predominantly been seen in high income countries where PCV coverage has been 
high, a booster dose of PCV in the second year of life has been used and where carriage 
is relatively low and largely confined to infants less than 5 years of age.   While infants 
are the predominant reservoir of carriage and the source of spread in many high income 
countries, a significant level of carriage in adults in countries across sub-Saharan Africa 
means that they are an important reservoir that is potentially less effectively addressed 
by the infant schedule.  
Although data are relatively sparse, as a consequence, the level of indirect protection 
offered to newborns and infants appears to be lower in low income setting with high 
rates of pneumococcal carriage in early infancy as well as a reservoir of carriage in older 
children and adults and incomplete vaccine coverage.  In addition, certain pneumococcal 
serotypes, including serotypes 1 and 5 cause a disproportionate amount of invasive 
disease in sub-Saharan Africa, are rarely carried, and hence likely to be less adequately 
controlled by indirect protection.  For this reason, the opportunities offered by both 
maternal and neonatal pneumococcal vaccination in low income settings warrant further 
consideration while ongoing data on carriage and disease is generated and other 
vaccination schedules are also explored. 
Unfortunately sample sizes and endpoints used have precluded any definitive evaluation 
of 23-valent pneumococcal polysaccharide vaccine in pregnancy.  The added value of the 
23-valent vaccine, in terms of its extended serotype coverage, will be eroded as the 
valency of the conjugate vaccines continues to increase. In addition, maternal 
immunization with a conjugate rather than a polysaccharide vaccine may result in higher 
antibody concentrations in the infant reflecting both the higher antibody concentrations 
generated in the mother and the higher antibody transfer ratio of the isotypes 
generated.  On this basis it is unlikely that further trials with the polysaccharide vaccine, 
as would be required before implementation was considered, will be warranted. 
Assuming an ongoing burden of disease, maternal immunization with PCV has the 
potential to prevent infection and perhaps carriage, over the first few months of life.  
Maternal vaccination may also facilitate the future use of the two-dose and potentially 
one-dose infant priming schedules which are now being explored, by providing protection 
in early life when one dose may be insufficient for direct protection. However, the 
potential for interference with infant PCV responses in the face of high maternally 
transferred antibody needs to be borne in mind and any potential biological effect of 
these reduced responses evaluated. Further research dissecting underlying immune 
mechanisms which might interfere with effector function or long term memory may also 
be required. 
In order to proceed with maternal or neonatal vaccination, definitive maternal and infant 
safety data, alongside information on immunogenicity, carriage and, where possible, 
other efficacy endpoints must be generated.  Evaluating serotype-specific interference 
between maternal antibodies and the subsequent response of the infant to the same 
conjugate vaccine will also be critical.  The effect of carrier protein (CRM197) specific 
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antibodies on the infant responses also needs to be assessed.  Finally, any interference 
with the likely co-administered vaccines (tetanus toxoid in mothers, hepatitis B, BCG and 
the oral poliovirus vaccine in infants) needs to be established.  Such data is required 
from low income settings were a future maternal vaccination strategy may be 
appropriate and trials to address these questions are already underway (Clintrials.gov 
NCT02628886) or are in the planning stage.        
Neonatal vaccination is an alternative approach which does not suffer from the potential 
drawback of high levels of maternal antibody which may impact on the subsequent 
response to the infant priming schedule.  However, the protection, in this case, is 
delayed and relies on an effective response to the conjugate vaccine at birth.  The 
delivery of the vaccine at this point has been shown to be safe and immunogenic and 
does not appear to compromise the potential long term protection the vaccines generate, 
at least if considering the response to a booster vaccination given at nine months.  In 
order to proceed with such a strategy, given the assessment of disease endpoints is no 
longer feasible, convincing immunogenicity and carriage data is likely to be required on a 
background of a clearly documented burden of disease.      
Five year view 
Within the next five years the potential utility of both maternal and newborn 
pneumococcal conjugate vaccination is likely to become much clearer.  The level of 
indirect protection from infant immunization delivered according to the EPI schedule in 
low-income, high-carriage settings over the initial months of life is likely to be 
established as programmes become embedded.  Nonetheless, schedule changes, 
particularly in low-income settings, are likely to mean that questions with this regard 
remain. 
Trials underway or planned are expected to provide definitive safety data on maternal 
pneumococcal conjugate vaccination and further strengthen the existing data set related 
to newborn vaccination, although the safety profile of the latter is already supportive.  
Further information on immunogenicity and carriage endpoint for both schedules will 
similarly be available and it is expected that the data set which thus exists will provide 
sufficient information to guide policy or decisions regarding large scale impact studies.  
In addition, there is currently a significant level of interest in alternative pneumococcal 
protein-based vaccines, with or without conjugated polysaccharides. It is hoped that the 
next five years will bring significant progress in this area which could also impact on the 
questions related to maternal and neonatal pneumococcal vaccination.  It is unlikely that 
any such vaccine would gain traction in the absence of clear indirect effects, at least 
when considering programmatic use.  However, the indirect protection may not be 
consistent across age groups, reflecting the complexities of pneumococcal epidemiology 
and the current lack of protein-based correlates of protection against disease or carriage.   
Thus within five years, new questions related to the role of maternal and newborn 
pneumococcal vaccination are also likely to have been generated while existing questions 
are addressed.         
Key issues 
 Pneumococcus is a significant pathogen in newborns and in early infancy, particularly 
in sub-Saharan Africa. 
 The seven, 10 and 13-valent pneumococcal-conjugate vaccines have been highly 
effective at preventing infection and carriage of the included pneumococcal serotypes 
in infants and children following their rollout in high, middle and low income countries.   
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 Due to differences in pneumococcal epidemiology the indirect protection seen in 
newborns in high income settings are unlikely to be translated consistently into low 
income countries and residual disease in early life seems likely to persist in the 
absence of additional interventions 
 Numerous trials of maternal vaccination with the 23-valent pneumococcal 
polysaccharide vaccines have been undertaken but a recent systemic review 
concluded that based on these trials there was insufficient evidence to determine a 
role for maternal pneumococcal vaccination in pregnancy 
 A single trial has been reported from the US using a nine-valent conjugate vaccine in 
pregnant women.  High levels of antibody transfer were reported but the infants in 
the maternal vaccination group had a higher level of acute otitis media than those in 
the control group.  Data in this paper is important but may need to be interpreted 
with some caution 
 Two trials have examined neonatal vaccination with a seven valent conjugate vaccine.  
In both the safety profile was reassuring and good responses to the vaccine 
administered at birth were documented. 
 Further clinical trials are currently underway or being planned to examine both 
maternal and neonatal pneumococcal-conjugate vaccination in low-income settings  
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Table 1:  Trials of maternal pneumococcal vaccination 
 Vaccine Control Population Gestation at 
vaccination  
Outcomes reported Ref 
     Safety Serological Carriage Disease Other  
The Gambia 
1991 - 1992  
23-valent 
Pn PS 
vaccine 
Men A and 
C PS 
vaccine 
150 pregnant 
women 
randomized: 
75 vaccine     
75 control 
Mean age: 
22 years 
Mean time between 
vaccination and 
delivery:             
6.3 weeks 
Mean estimated 
gestation at 
vaccination:  
38 weeks 
 
No significant side-
effects recorded in 
vaccinated women  
No apparent 
differences in 
maternal deaths, still 
births, infant deaths - 
small number of 
events 
Serotypes tested: 1, 3, 5, 6B, 14, 19F 
Higher cord blood Pn PS IgG in vaccinated compared to 
controls  for 4 of 5 serotypes tested 
Cord/Maternal IgG ratio between 0.24 to 0.52 according to Pn 
PS and group 
Rapid Pn PS IgG decline in infants - levels comparable 
between vaccine and control groups by 2 to 4 months. 
Reduced Pn PS IgG responses associated with malaria 
parasitaemia at the time of vaccination  for 2 of 6 serotypes 
tested 
Not tested Small number 
of events.   
No apparent 
differences in 
diseases 
outcomes 
(meningitis, 
pneumonia, 
otitis media) 
Significantly 
higher 
colostrum and 
breast milk 
secretory IgA 
concentrations 
and avidity 
indices  (type 
6B, 6B and 14 
to 6 months; 
type 19F to 4 
months) in 
vaccine 
compared to 
control mothers 
[46, 
50, 
58] 
Papua New 
Guinea 
1991 - 1994 
23-valent 
Pn PS 
vaccine 
Not 
vaccinated 
437 pregnant 
women 
235 Vaccine 
202 Control 
Mean interval from 
vaccination to 
delivery was 8.5 
weeks 
No difference in the 
number of still births 
in vaccinated mothers 
compared to 
background 
population. 
No other safety 
concerns described 
Serotypes tested:  5, 7F, 14, 23F 
Significant increase in GMC to 3 of 4 serotypes tested (no 
increase in serotype 7F) 
1.4 to 2.7 fold rise in concentration across the 3 serotypes in 
mothers 
Mean cord/maternal IgG ratio 0.57 across all serotypes tested 
GMC significantly higher in maternal and cord blood samples 
in vaccinated compared to controls at delivery 
Infant GMC significantly higher in vaccinated compared to 
control groups to  30-59 days (type 5, 7F, 23F) and 119 days 
(type 14) 
Infants in both vaccine and control groups responded to a 
dose of the 23-valent Pn PS vaccine given at 8 to 9 months of 
age.  No significant differences between groups.  3.1 to 7.5 
fold rise in antibody concentrations according to group and 
serotype  
Not reported Mortality from 
acute lower 
respiratory 
infections 
reported to be 
lower in vaccine 
group compared 
to controls (17 
versus 30 per 
1000 live-
births) but 
numbers of 
events low (4 
and 6 events 
respectively) 
 [52] 
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Philippines 
1994 - 1995 
23-valent 
Pn PS 
vaccine +    
Hib-TT 
conjugate 
vaccine + 
TT vaccine 
 
 
TT vaccine 
alone 
160 pregnant 
women 
randomized, 
open label 
106 vaccine 
54 control 
Mean age:   
26.8 years  
Mean time between 
vaccination and 
delivery: 
10.9 weeks 
Mean gestation at 
vaccination: 
27.3 weeks 
Local and systemic 
adverse events in 
keeping with those 
expected 
No pregnancy or 
infant outcome data 
reported. 
Serotypes tested: 1, 5, 6B, 14, 18C, 19F 
Significant increases in GMC for the 6 serotypes tested.  
Mean 5.4 fold rise in vaccinated mothers 
Pn PS IgG in cord blood 2.9 to 5.7 times higher in vaccine 
than in control group. 
89% of Pn PS IgG levels in cord blood samples > 0.35ug/mL 
in vaccinated group compared to 57% in control group 
Cord/Maternal IgG ratio estimated to be between 0.52 and 
0.88 for the 6 serotypes tested  
No correlation between gestation in weeks at time of 
vaccination and cord blood antibody concentrations 
Not tested Not reported  [44, 
45] 
 Infants 
vaccinated 
with 23-
valent Pn 
PS vaccine 
at 7 or 17 
weeks 
Infants 
vaccinated 
with 23-
valent Pn 
PS vaccine 
at 7 weeks 
   Serotypes tested: 1, 5, 6B, 14, 18C, 19F 
Infants of vaccinated mothers had a higher Pn PS IgG GMC at 
7 weeks compared to infants born to mothers in control 
group 
23% (type 1) and 6% (type 5) of infants born to vaccinated 
mothers had a 2 fold rise in Pn PS IgG compared to 63% and 
(type 1) and 28% (type 5) of infants born to mothers in 
control group.   
Post-vaccination Pn PS IgG higher in infants born to 
vaccinated mothers reflecting ongoing effects of maternal 
antibodies at 12 weeks   
No responses above declining maternal antibodies to 6B, 14, 
18C and 19F 
   [48] 
United 
States 
1995 - 1996  
23-valent 
Pn PS 
vaccine 
Hib-CRM197 
conjugate 
vaccine 
60 pregnant 
women 
randomized, 
double blinded: 
20 vaccine 
40 control 
Mean age: 
30.2 (vaccine) 
31.6 (control) 
Mean time between 
vaccination and 
delivery: 
43.6 days (vaccine) 
44.0 days (control) 
Mean gestation at 
vaccination: 
33.3 weeks 
33.0 weeks 
No SAE likely to be 
attributed to the 
vaccine in mothers 
No still births or infant 
deaths 
No significant 
differences in the 
rates of adverse 
events between 
vaccine and control 
group  
Serotypes tested: 6B, 14, 19F, 23F 
Pn PS IgG, IgG1 and OPA significantly higher in vaccine 
compared to controls at deliver for 4 of 4  serotypes tested 
Pn PS IgG2 significantly higher in vaccine compared to 
control group for 2 of 4 serotypes tested 
Cord/Maternal IgG mean ratio for 4 serotypes tested 0.89 
Higher cord blood IgG for 4 of 4 serotypes tested in vaccine 
compared to control groups.  Persistence to 2 and 6 months 
dependent on Pn serotype and IgG isotype tested. 
Higher 
colonisation 
in the infants 
of control 
compared to 
vaccinated 
mothers in 
nasal washes 
taken at 
between 2 
and 15 
months of 
age.  
Not reported  Significantly 
higher breast 
milk IgA in 
vaccinated 
compared to 
control mothers 
at 2 months 
Significantly 
higher breast 
milk IgG in 
vaccinated 
compared to 
control mothers 
at 2 months for 
2 of the 4 
serotypes 
tested 
[47] 
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United 
States 
2000 - 2003 
9-valent Pn 
PS-CRM197 
conjugate 
vaccine 
 
Saline 
placebo              
 
                                        
152 pregnant 
women 
74 Vaccine 
78 Control
Vaccinated at 30 to 
35 weeks gestation 
Vaccine well tolerated 
by maternal and 
infant participant 
Serotypes tested: 4, 6B, 9V, 14, 18C, 19F, 23F (plus 1 and 5 
in 9-valent vaccine) 
Significantly higher maternal GMC to 7 serotypes in 7-valent 
PS-CRM197 conjugate vaccine comparing vaccine versus 
control groups 
Significantly higher cord blood GMC to 7 serotypes in 7-valent 
PS-CRM197 conjugate vaccine comparing vaccine versus 
control groups 
GMC inferior in the vaccine group compared to the control 
group at 7 months (one month after third dose of the 7-
valent vaccine) for 7 of 7 serotypes 
GMC inferior in the vaccine group compared to the control 
group at 7 months (one month after fourth (booster) dose of 
the 7-valent vaccine) for 4 of 7 serotypes 
GMC higher in infants born to mothers in vaccine compared 
to control groups at 6 and 7 months for serotypes 1 and 5 (in 
9 valent vaccine received by mothers but not in 7 valent 
vaccine received by infants)  
Not reported First episode of 
acute otitis 
media (AOM) 
occurred at 15 
days in vaccine 
group compared 
to 114 days in 
control group 
AOM and otitis 
media (OM) free 
rates over the 
first six months 
significant 
higher in control 
group (AOM 
89% versus 
74%; OM 85% 
versus 68%) 
The apparent 
effect was lost 
after 6 months 
 [56] 
Bangladesh  
2004 - 2005 
23-valent 
Pn PS 
vaccine 
Inactivated 
influenza 
vaccine* 
340 pregnant 
women, 
randomized, 
double-blind 
168 Vaccine 
172 Control 
 
Mean interval 
between vaccination 
and birth 56 days in 
vaccine group, 54 
days in control 
group 
No difference in the 
number of pregnancy 
outcomes or severe 
adverse events 
between the mothers 
in the vaccine and 
control groups 
Minor local and 
systemic 
reactogenicity only 
Serotypes tested:  4, 6B, 9V, 14, 19F, 18C, 23F, 1, 5 
At delivery 86.4 to 100.0% of mothers in the vaccine group 
and 30.0 to 96.5% of mothers in the control group had Pn PS 
IgG concentrations of >0.35µg/mL, dependent on serotype 
At 12 months post-delivery 86.7 to 100.0% of mothers in the 
vaccine group and 55.0 to 100.0% of mothers in the control 
group had Pn PS IgG concentrations of >0.35µg/mL 
according to serotype. 
Not reported Not reported  [59, 
60] 
Brazil 
2005 - 2006 
23-valent 
Pn PS 
vaccine 
Not 
vaccinated 
150 pregnant 
women, 
randomized, 
open label 
45 Vaccine  
47 Control  
Vaccinated at 30 to 
34 weeks gestation 
No significant 
relationship between 
vaccination use and 
premature labour 
Minimal local or 
systemic reactions to 
the vaccine 
Not reported No difference 
in 
pneumococcal 
colonization 
rates up to 6 
months of 
ages. 
Non-
significant 
differences in 
serotypes 
carried - 
small number 
of events 
overall 
No difference in 
acute 
respiratory 
infections or 
antibiotic use 
between birth 
and 6 months of 
ages in infants 
 [51, 
61] 
47 Vaccine 
(following 
delivery)  
 
(11 exclusions) 
Vaccinated following 
delivery 
Brazil 
Dates not 
provided 
23-valent 
Pn PS 
vaccine 
No control 
group 
included 
46 pregnant 
HIV positive 
women 
45 on anti-
retroviral 
treatment 
Vaccinated at 32 to 
34 weeks gestation, 
mean 33 weeks 
Median interval 
between vaccination 
and birth 40 days 
(range 21 to 78 
days) 
No serious adverse 
reactions attributable 
or possible 
attributable to the 
vaccine were 
observed. 
Minimal reactogenicity 
No still births or infant 
deaths 
2 infants vertically 
infected with HIV 
Serotypes tested: 1, 3, 5, 6B, 9V, 14 
Significant increases in GMC to 5 of 6 serotypes tested (no 
increase in serotype 3 titres) 
1.5 to 2.9 fold rise in concentrations across the 5 serotypes in 
mothers 
Strong correlation between maternal and infant IgG 
concentrations.  Pearson's correlation coefficient 0.767 to 
0.931. 
Infant/maternal IgG ratios 0.459 (type 9V) to 0.718 (type 3) 
Time for GMC to fall to 0.35µg/mL in infants ranged from 0.6 
months (type 3) to 2.7 months (type 6B).  
Not reported Not reported  [49] 
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Bangladesh 
Dates not 
provided 
23-valent 
Pn PS 
vaccine 
Men A, C, 
W, Y PS 
vaccine 
70 pregnant 
women, 
randomized, 
double blinded 
36 vaccine 
34 control 
Mean time between 
vaccination and 
delivery: 
7 weeks  
Mean gestation at 
vaccination: 
32 weeks 
Vaccines well 
tolerated in both 
groups with a profile 
of local reactions as 
expected 
No differences in 
number of low birth 
weight (<2.5kg) or 
premature (<37 
week) infants 
between vaccine and 
control groups. 
2 full term unrelated 
still births in the 
vaccine group 
No congenital defects 
or serious illnesses 
noted in any infant up 
to 22 weeks of age. 
Serotypes tested: 6B, 19F 
Significantly higher GMC in vaccine compared to control 
mothers at delivery  (13.8 and 17.4 compared to 5.3 and 
4.7µg/mL for 6B and 19F respectively) 
Maternal and cord blood Pn PS IgG concentrations highly 
correlated.  Spearman coefficients 0.81 and 0.90 for type 6B 
and 19F respectively. 
Cord/Maternal IgG mean ratio 0.56 (type 6B) and 0.59 (type 
19F)  
Cord/Maternal IgG1 mean ratio 0.88 (type 19F)  and 1.20 
(tetanus toxoid) 
Cord/Maternal IgG2 mean ratio 0.45 (type 19F)  and 0.80 
(tetanus toxoid) 
Infants in vaccine group had GMC 2 to 3 fold higher for 6B 
and 19F up to 22 weeks postnatal age. 
 
Half of infants 
colonised by 
3 months and 
three 
quarters by 6 
months with 
no differences 
between 
groups. 
VT not 
reported 
separately 
Not reported Breast milk IgA 
3x higher in 
colostrum of 
vaccinated 
mothers - 
falling to 
undetectable 
levels by 2 
weeks (6B) 
Breast milk IgA 
7x higher in 
colostrum of 
vaccinated 
mothers - 
remaining at 
least 3x higher 
up to 5 months 
(19A) 
[43] 
Australia -  
Indigenous 
Population, 
Northern 
Territory 
23-valent 
Pn PS 
vaccine 
Not 
vaccinated 
or 
23-valent 
Pn PS 
vaccine 
given to 
mother 
within 72 
hours of 
delivery  
227 pregnant 
women 
randomized, 
mothers not 
blinded. 
Investigators 
incompletely 
blinded for 
disease 
endpoint 
75 vaccine in 
pregnancy 
75 vaccine 
given to mother 
at birth 
77 control 
Median age 23 
to 25 years 
Median time 
between vaccination 
and delivery 6 
weeks  
Range 1 to 10 weeks 
Inter-quartile range 
4 to 6 weeks 
Median gestation at 
deliver 39 weeks in 
all groups 
 
Note that 84 to 89% 
of infants had 
received > 2 doses 
of the 7 valent 
Prevenar™ vaccine 
of the 10-valent 
Synflorix™ vaccine 
by the time of the 7 
month primary 
endpoint 
assessments 
 
 
Low local and 
systemic 
reactogenicity 
following vaccination 
in pregnancy 
Median birth weight 
3.2 - 3.4kg 
No differences in: 
Low birth weight 
(<2.5kg) - 5 to 9% 
Prematurity (<37 
weeks) - 3 to 9% 
Special/Intensive Care 
admission - 19 to 
21% 
Higher cord blood antibody IgG GMC in mothers vaccinated in 
pregnancy compared to control mothers or mothers 
vaccinated at delivery (19A, 15B, 33F, 10A shown) 
Indistinguishable by 7 months for vaccine types in 23-valent 
but not 7 or 10 valent vaccine 
Infant immunogenicity data to be reported separately 
23-valent 
vaccine-type 
pneumococcal 
carriage at 7 
months 
Controls: 
17/66 (26%) 
Maternal 
vaccination 
group:  
12/67 (18%) 
VE 30%          
(-34 to 64) 
Birth 
vaccination 
group: 
12/66 (18%) 
VE 29%       
(-36 to 63) 
 
No carriage 
differences at 
1 or 2 
months of 
age either. 
 
Ear disease 
Controls: 47/66 
(71%) 
Maternal 
vaccination 
group:  
42/67 (63%) 
VE 12%          
(-12 to 31) 
Birth 
vaccination 
group: 
50/66 (76%) 
VE -6%           
(-31 to 13) 
 
Breast milk IgA 
GMC in mothers 
vaccinated in 
pregnancy > 
mothers 
vaccinated at 
delivery > 
control mothers 
Differences 
persist at 7 
months 
(19A, 15B, 33F, 
10A shown) 
[16] 
Pn - pneumococcal; PS = polysaccharide; IgA - Immunoglobulin A; IgG - Immunoglobulin G; VT - vaccine-type; NVT - non-vaccine type; Hib - H.influenzae type b; Men A - 
meningococcal serogroup A; TT - tetanus toxoid; GMC - geometric mean concentrations; OPA - opsonophagocytic activity; VE - vaccine efficacy (1- risk ratio) with 95% 
confidence intervals  *study conducted to assess influenza vaccine  
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Table 2: Trials of neonatal pneumococcal vaccination 
 Vaccine Neonatal 
group 
Control 
group 
Outcomes reported Ref 
    Safety Serological Carriage Disease Other  
Kenya 
2004 - 
2007 
7-valent 
Pn PS-
CRM197 
conjugate 
150 infants 
vaccinated at 
0, 10 and 14 
weeks of age 
150 infants 
vaccinated at 
6, 10 and 14 
weeks of age 
No significant 
differences in 
fever or local 
reactogenicity 
between 
groups 
No significant 
differences in 
adverse 
event or 
serious 
adverse 
event rate 
One death, 
judged 
unrelated to 
vaccination, 
occurred in 
each group  
Serotypes tested:  4, 6B, 9V, 14, 18C, 19F, 27F (serotypes incorporated into 7 valent vaccine). 
At 18 weeks (4 weeks post primary schedule): 
 There was no significant difference in the percentage of infants with Pn PS IgG > 0.35µg/mL (87 - 
99% for neonatal group compared to 92 - 100% for control group). 
 There were significant differences in the percentage of infants with Pn PS IgG > 1.0µg/mL for 3 of 7 
serotypes (serotypes 4, 18C, 19F) in the neonatal compared to the control group 
 GMC were significantly lower for 4 of 7 serotypes (serotypes 4, 9V, 18C, 19F) in neonatal group 
compared to control group. 
 The geometric mean avidity indices was significantly higher for 3 of 4 serotypes tested (serotype 4, 
6B, 19F) compared to the control group 
 There was a significant downward trend in the GMC at 18 weeks moving from the highest quintile of 
cord blood GMC to the lowest quintile (serotypes 6B, 9V, 14 and 19F in control group and serotypes 
6B 14 and 23F in neonatal group) - inhibitory effect of maternal antibodies 
At 36 weeks (20 weeks post primary schedule): 
 There was no difference in the percentage of infants with Pn PS IgG > 0.35ug/mL (56 - 92% for 
neonatal group compared to 60 to 95% for control group). 
 There were no  significant differences in the percentage of infants with Pn PS IgG > 1.0µg/mL in the 
neonatal compared to the control group 
 GMC remained significantly lower for 1 of 7 serotypes (serotype 4) in neonatal group compared to 
control group.  
 The geometric mean avidity indices remained significantly higher for 1 of 4 serotypes tested 
(serotype 19F) compared to control group 
 There were no significant differences in the response to a booster of either a 7 valent Pn PS-CRM197 
conjugate vaccine or a 23-valent Pn PS vaccine between the two groups 
There were no 
significant differences in 
VT or NVT carriage at 
either 18 or 36 weeks 
Total VT carriage 
prevalence was higher 
in the neonatal group at 
18 (p=0.28)  and 36 
weeks (p=0.07) 
Total NVT carriage 
prevalence was higher 
in the control group at 
18 (p=0.25)  and 36 
weeks (p=0.08) 
 
 
Not 
reported 
 [54] 
Papua 
New 
Guinea 
2005 - 
2007 
7-valent 
Pn PS-
CRM197 
conjugate 
101 infants 
vaccinated at 
0 1 and 2 
months of 
age 
105 infants 
vaccinated at 
1, 2 and 3 
months of 
age 
 
(106 infants 
not 
vaccinated) 
 
No serious 
reactions 
within 1 hour 
of vaccination 
in any group. 
Lower levels 
of local 
reactogenicity 
in neonatal 
compare to 
vaccinated 
control group 
No significant 
differences in 
SAE rate 
between the 
three groups 
Serotypes tested:  4, 6B, 9V, 14, 18C, 19F, 27F (plus 2, 5 and 7F NVT) 
At birth: 
 90.2 to 100% of infants had a Pn PS IgG > 0.35µg/mL and 70.7 to 97.7% of infants had a Pn PS 
IgG > 1.0µg/mL according to serotype 
At 2 months (following 2 vaccination in the neonatal group and 1 vaccination in the control group) 
 80.9 to 100.0% to infants in the neonatal group compared to 71.0 to 97.8% of infants in the 
control group had a Pn PS IgG > 0.35µg/mL.  Percentages higher in the neonatal group for all 
serotypes 
At 4 months (following 3 vaccinations in both groups) 
 71.8 to 98.8% of infants in the neonatal group compared to 88.9 to 100% of infants in the control 
group had a Pn PS IgG > 0.35µg/mL.  Percentages higher in the control group for all serotypes 
Infants in both the neonatal and control groups responded to a dose of the 23-valent Pn PS vaccine 
with a mean 6.4 fold rise in Pn PS IgG compared to a 1.9 fold rise in the unvaccinated infants taken to 
indicate the induction of PS-specific B-cell memory by both the neonatal and the control schedule.  No 
significant differences in IgG rise between the neonatal and the control schedule. 
 No 
significant 
differences 
in acute 
lower 
respiratory 
infection 
rate 
between 
groups 
No 
significant 
differences 
in the rates 
of IPD 
between 
groups 
(n=7 in 
total) 
 [57] 
Pn - pneumococcal; PS = polysaccharide; IgA - Immunoglobulin A; IgG - Immunoglobulin G; VT - vaccine-type; NVT - non-vaccine type; Hib - H.influenzae type b; Men A - 
meningococcal serogroup A; TT - tetanus toxoid; GMC - geometric mean concentrations; OPA - opsonophagocytic activity;  *study conducted to assess influenza vaccine 
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